Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 28Genitourinary 28Lymphoid 17Other hematologic neoplasm 9Breast 6Gastrointestinal 5Classical hematology 5Thoracic 4Sarcoma 4Other 4Myeloid 4Head & Neck 4Gynecologic 4Dermatologic 2CNS 1

Conditions

Melanoma 3141Skin Neoplasms 554Lymphoma, T-Cell, Cutaneous 543Carcinoma, Non-Small-Cell Lung 421Neoplasms 388Mycosis Fungoides 369Breast Neoplasms 364Carcinoma, Basal Cell 360Keratosis, Actinic 335Sezary Syndrome 331Lymphoma, Non-Hodgkin 312Carcinoma, Renal Cell 308Neoplasm Metastasis 304Lymphoma 300Leukemia, Lymphocytic, Chronic, B-Cell 292Lymphoma, Large B-Cell, Diffuse 287Lymphoma, Follicular 286Hodgkin Disease 275Uveal Melanoma 274Lymphoma, B-Cell, Marginal Zone 273Lymphoma, Mantle-Cell 272Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Burkitt Lymphoma 258Lymphoma, Large-Cell, Immunoblastic 248Lung Neoplasms 236Colorectal Neoplasms 232Ovarian Neoplasms 214Lymphoma, Large-Cell, Anaplastic 206Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 203Multiple Myeloma 199

Interventions

veliparib 1ripretinib 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Renal Insufficiency × Dermatologic × Clear all
NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Active not recruiting
94 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡